Xiamen Innovax Biotech Co., Ltd.
Established in March of 2005, Xiamen Innovax Biotech Co., Ltd. is a wholly-owned subsidiary of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., a well-known private enterprise in China, in the biomedical field. Relying on the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD), which it established together with Xiamen University, the company has made remarkable achievements in promoting innovative vaccine industrialization.
Business Type:Manufacturer
Country/Region:China
Ddu Verified
HOT Rank
[Quality standard] Company Standard (YBS01402011)
[Suitable population] This product is suitable for susceptible population aged 16 and above. It is recommended for individuals exposed to high risk of hepatitis E virus infection, such as those engaged in animal husbandry and catering, students, officers and soldiers, women of childbearing age, travelers to endemic areas and so on.
[Specification] 30µg/0.5ml/dose
[Route of Administration] 3 doses of intramuscular injection following the 0, 1 months, 6 months schedule, that is the first dose on the first day, the second dose one month after the first injection，and the third dose six months after the first injection.
[Shelf life] 2-8℃ for 36 months
[Highlights]
•Launched in Oct. 2012, China
•The world's first vaccine against hepatitis E
•Up to 4.5 years, the long-term efficacy against clinical HE was 93.3% (78.6-97.9) and 86.8% (71.0-94.0) in per-protocol and intention-to-treat analysis, respectively.
•Complete phase I, II, III, IV Clinical Trial conducted in China
